health
Phase 2 trial reports major responses with ivonescimab in resectable lung cancer
A phase 2 trial in resectable non-small cell lung cancer found a major pathological response in 70.1% of patients who underwent surgery after perioperative ivonescimab plus chemotherapy. The study was noncomparative, and median event-free survival was not mature at the analysis cutoff.